Dyne Therapeutics, Inc. (DYN) Stock Competitors & Peer Comparison
See (DYN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DYN | $22.21 | +4.47% | 3.7B | -6.90 | -$3.22 | N/A |
| VRTX | $496.73 | -0.58% | 126B | 26.38 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $623.54 | -1.31% | 64.2B | 13.67 | $45.63 | +0.58% |
| ARGX | $927.77 | +1.68% | 57.4B | 83.73 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.38 | -5.44% | 41.1B | -2.27 | -$4.15 | N/A |
| ALNY | $301.03 | +2.56% | 40.2B | 54.24 | $5.55 | N/A |
| RVMD | $187.28 | -2.77% | 39.8B | -26.49 | -$7.07 | N/A |
| ONC | $284.97 | -1.73% | 30.5B | 63.75 | $4.47 | N/A |
Stock Comparison
DYN vs VRTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, VRTX has a market cap of 126B. Regarding current trading prices, DYN is priced at $22.21, while VRTX trades at $496.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas VRTX's P/E ratio is 26.38. In terms of profitability, DYN's ROE is -0.58%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, DYN is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check VRTX's competition here
DYN vs VRNA Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DYN is priced at $22.21, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DYN's ROE is -0.58%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, DYN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check VRNA's competition here
DYN vs REGN Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, REGN has a market cap of 64.2B. Regarding current trading prices, DYN is priced at $22.21, while REGN trades at $623.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas REGN's P/E ratio is 13.67. In terms of profitability, DYN's ROE is -0.58%, compared to REGN's ROE of +0.14%. Regarding short-term risk, DYN is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check REGN's competition here
DYN vs ARGX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ARGX has a market cap of 57.4B. Regarding current trading prices, DYN is priced at $22.21, while ARGX trades at $927.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ARGX's P/E ratio is 83.73. In terms of profitability, DYN's ROE is -0.58%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, DYN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ARGX's competition here
DYN vs SGEN Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DYN is priced at $22.21, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DYN's ROE is -0.58%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DYN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check SGEN's competition here
DYN vs RVMDW Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, RVMDW has a market cap of 41.1B. Regarding current trading prices, DYN is priced at $22.21, while RVMDW trades at $9.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas RVMDW's P/E ratio is -2.27. In terms of profitability, DYN's ROE is -0.58%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, DYN is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check RVMDW's competition here
DYN vs ALNY Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ALNY has a market cap of 40.2B. Regarding current trading prices, DYN is priced at $22.21, while ALNY trades at $301.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ALNY's P/E ratio is 54.24. In terms of profitability, DYN's ROE is -0.58%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, DYN is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ALNY's competition here
DYN vs RVMD Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, RVMD has a market cap of 39.8B. Regarding current trading prices, DYN is priced at $22.21, while RVMD trades at $187.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas RVMD's P/E ratio is -26.49. In terms of profitability, DYN's ROE is -0.58%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, DYN is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RVMD's competition here
DYN vs ONC Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ONC has a market cap of 30.5B. Regarding current trading prices, DYN is priced at $22.21, while ONC trades at $284.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ONC's P/E ratio is 63.75. In terms of profitability, DYN's ROE is -0.58%, compared to ONC's ROE of +0.12%. Regarding short-term risk, DYN is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ONC's competition here
DYN vs MRNA Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, MRNA has a market cap of 27.8B. Regarding current trading prices, DYN is priced at $22.21, while MRNA trades at $70.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas MRNA's P/E ratio is -8.59. In terms of profitability, DYN's ROE is -0.58%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, DYN is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MRNA's competition here
DYN vs ROIV Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ROIV has a market cap of 25.5B. Regarding current trading prices, DYN is priced at $22.21, while ROIV trades at $35.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ROIV's P/E ratio is -39.27. In terms of profitability, DYN's ROE is -0.58%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, DYN is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ROIV's competition here
DYN vs BNTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, BNTX has a market cap of 23.5B. Regarding current trading prices, DYN is priced at $22.21, while BNTX trades at $93.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas BNTX's P/E ratio is -20.14. In terms of profitability, DYN's ROE is -0.58%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, DYN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BNTX's competition here
DYN vs INSM Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, INSM has a market cap of 23.1B. Regarding current trading prices, DYN is priced at $22.21, while INSM trades at $106.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas INSM's P/E ratio is -18.54. In terms of profitability, DYN's ROE is -0.58%, compared to INSM's ROE of -1.30%. Regarding short-term risk, DYN is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check INSM's competition here
DYN vs UTHR Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, DYN is priced at $22.21, while UTHR trades at $541.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas UTHR's P/E ratio is 20.00. In terms of profitability, DYN's ROE is -0.58%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DYN is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check UTHR's competition here
DYN vs INCY Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, INCY has a market cap of 22.6B. Regarding current trading prices, DYN is priced at $22.21, while INCY trades at $113.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas INCY's P/E ratio is 15.24. In terms of profitability, DYN's ROE is -0.58%, compared to INCY's ROE of +0.29%. Regarding short-term risk, DYN is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check INCY's competition here
DYN vs BGNE Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DYN is priced at $22.21, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DYN's ROE is -0.58%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, DYN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BGNE's competition here
DYN vs DNA-WT Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, DYN is priced at $22.21, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, DYN's ROE is -0.58%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, DYN is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check DNA-WT's competition here
DYN vs NBIX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, DYN is priced at $22.21, while NBIX trades at $168.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas NBIX's P/E ratio is 24.35. In terms of profitability, DYN's ROE is -0.58%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, DYN is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check NBIX's competition here
DYN vs GMAB Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, GMAB has a market cap of 16.9B. Regarding current trading prices, DYN is priced at $22.21, while GMAB trades at $27.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas GMAB's P/E ratio is 19.76. In terms of profitability, DYN's ROE is -0.58%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, DYN is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check GMAB's competition here
DYN vs ASND Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ASND has a market cap of 16.6B. Regarding current trading prices, DYN is priced at $22.21, while ASND trades at $266.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ASND's P/E ratio is -110.21. In terms of profitability, DYN's ROE is -0.58%, compared to ASND's ROE of -56.42%. Regarding short-term risk, DYN is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ASND's competition here
DYN vs JAZZ Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, DYN is priced at $22.21, while JAZZ trades at $240.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas JAZZ's P/E ratio is 18.74. In terms of profitability, DYN's ROE is -0.58%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, DYN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check JAZZ's competition here
DYN vs BBIO Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, BBIO has a market cap of 14.6B. Regarding current trading prices, DYN is priced at $22.21, while BBIO trades at $74.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas BBIO's P/E ratio is -19.91. In terms of profitability, DYN's ROE is -0.58%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, DYN is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BBIO's competition here
DYN vs EXEL Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, EXEL has a market cap of 13.6B. Regarding current trading prices, DYN is priced at $22.21, while EXEL trades at $54.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas EXEL's P/E ratio is 16.25. In terms of profitability, DYN's ROE is -0.58%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, DYN is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check EXEL's competition here
DYN vs IONS Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, IONS has a market cap of 13.1B. Regarding current trading prices, DYN is priced at $22.21, while IONS trades at $79.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas IONS's P/E ratio is -46.10. In terms of profitability, DYN's ROE is -0.58%, compared to IONS's ROE of -0.59%. Regarding short-term risk, DYN is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check IONS's competition here
DYN vs KRTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DYN is priced at $22.21, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DYN's ROE is -0.58%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DYN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check KRTX's competition here
DYN vs AXSM Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, AXSM has a market cap of 12.6B. Regarding current trading prices, DYN is priced at $22.21, while AXSM trades at $244.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas AXSM's P/E ratio is -63.91. In terms of profitability, DYN's ROE is -0.58%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, DYN is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check AXSM's competition here
DYN vs MDGL Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, DYN is priced at $22.21, while MDGL trades at $536.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas MDGL's P/E ratio is -41.95. In terms of profitability, DYN's ROE is -0.58%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, DYN is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MDGL's competition here
DYN vs ARWR Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ARWR has a market cap of 11.5B. Regarding current trading prices, DYN is priced at $22.21, while ARWR trades at $81.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ARWR's P/E ratio is -37.91. In terms of profitability, DYN's ROE is -0.58%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, DYN is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ARWR's competition here
DYN vs SMMT Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, SMMT has a market cap of 11.3B. Regarding current trading prices, DYN is priced at $22.21, while SMMT trades at $14.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas SMMT's P/E ratio is -9.11. In terms of profitability, DYN's ROE is -0.58%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, DYN is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check SMMT's competition here
DYN vs RNAM Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DYN is priced at $22.21, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DYN's ROE is -0.58%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, DYN is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RNAM's competition here
DYN vs TECH Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, DYN is priced at $22.21, while TECH trades at $70.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas TECH's P/E ratio is 36.42. In terms of profitability, DYN's ROE is -0.58%, compared to TECH's ROE of +0.05%. Regarding short-term risk, DYN is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TECH's competition here
DYN vs BMRN Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, DYN is priced at $22.21, while BMRN trades at $57.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas BMRN's P/E ratio is 27.51. In terms of profitability, DYN's ROE is -0.58%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, DYN is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BMRN's competition here
DYN vs KRYS Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, KRYS has a market cap of 11B. Regarding current trading prices, DYN is priced at $22.21, while KRYS trades at $371.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas KRYS's P/E ratio is 49.69. In terms of profitability, DYN's ROE is -0.58%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, DYN is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check KRYS's competition here
DYN vs CYTK Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CYTK has a market cap of 10.6B. Regarding current trading prices, DYN is priced at $22.21, while CYTK trades at $85.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CYTK's P/E ratio is -14.61. In terms of profitability, DYN's ROE is -0.58%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, DYN is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CYTK's competition here
DYN vs RXDX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DYN is priced at $22.21, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DYN's ROE is -0.58%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DYN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RXDX's competition here
DYN vs KYMR Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, KYMR has a market cap of 9.4B. Regarding current trading prices, DYN is priced at $22.21, while KYMR trades at $114.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas KYMR's P/E ratio is -32.48. In terms of profitability, DYN's ROE is -0.58%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, DYN is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check KYMR's competition here
DYN vs CORT Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CORT has a market cap of 9.3B. Regarding current trading prices, DYN is priced at $22.21, while CORT trades at $86.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CORT's P/E ratio is 248.43. In terms of profitability, DYN's ROE is -0.58%, compared to CORT's ROE of +0.08%. Regarding short-term risk, DYN is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CORT's competition here
DYN vs HALO Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, HALO has a market cap of 9.3B. Regarding current trading prices, DYN is priced at $22.21, while HALO trades at $78.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas HALO's P/E ratio is 16.94. In terms of profitability, DYN's ROE is -0.58%, compared to HALO's ROE of +1.26%. Regarding short-term risk, DYN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check HALO's competition here
DYN vs IBRX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, IBRX has a market cap of 9.2B. Regarding current trading prices, DYN is priced at $22.21, while IBRX trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas IBRX's P/E ratio is -27.36. In terms of profitability, DYN's ROE is -0.58%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, DYN is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check IBRX's competition here
DYN vs NUVL Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, DYN is priced at $22.21, while NUVL trades at $123.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas NUVL's P/E ratio is -21.70. In terms of profitability, DYN's ROE is -0.58%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, DYN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check NUVL's competition here
DYN vs ABVX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, DYN is priced at $22.21, while ABVX trades at $133.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ABVX's P/E ratio is -69.70. In terms of profitability, DYN's ROE is -0.58%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, DYN is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ABVX's competition here
DYN vs ALKS Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ALKS has a market cap of 8.7B. Regarding current trading prices, DYN is priced at $22.21, while ALKS trades at $52.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ALKS's P/E ratio is 55.15. In terms of profitability, DYN's ROE is -0.58%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, DYN is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ALKS's competition here
DYN vs IMGN Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DYN is priced at $22.21, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DYN's ROE is -0.58%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DYN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check IMGN's competition here
DYN vs TGTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, DYN is priced at $22.21, while TGTX trades at $54.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas TGTX's P/E ratio is 18.88. In terms of profitability, DYN's ROE is -0.58%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, DYN is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TGTX's competition here
DYN vs PCVX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, DYN is priced at $22.21, while PCVX trades at $58.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas PCVX's P/E ratio is -8.45. In terms of profitability, DYN's ROE is -0.58%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, DYN is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check PCVX's competition here
DYN vs BPMC Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DYN is priced at $22.21, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DYN's ROE is -0.58%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, DYN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BPMC's competition here
DYN vs CERE Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DYN is priced at $22.21, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CERE's P/E ratio is -16.47. In terms of profitability, DYN's ROE is -0.58%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DYN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CERE's competition here
DYN vs APGE Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, DYN is priced at $22.21, while APGE trades at $132.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas APGE's P/E ratio is -30.65. In terms of profitability, DYN's ROE is -0.58%, compared to APGE's ROE of -0.33%. Regarding short-term risk, DYN is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check APGE's competition here
DYN vs IMVT Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, DYN is priced at $22.21, while IMVT trades at $38.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas IMVT's P/E ratio is -14.43. In terms of profitability, DYN's ROE is -0.58%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, DYN is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check IMVT's competition here
DYN vs PTGX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, PTGX has a market cap of 7.9B. Regarding current trading prices, DYN is priced at $22.21, while PTGX trades at $122.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas PTGX's P/E ratio is -67.72. In terms of profitability, DYN's ROE is -0.58%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, DYN is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check PTGX's competition here
DYN vs RYTM Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, RYTM has a market cap of 7.6B. Regarding current trading prices, DYN is priced at $22.21, while RYTM trades at $111.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas RYTM's P/E ratio is -35.47. In terms of profitability, DYN's ROE is -0.58%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, DYN is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RYTM's competition here
DYN vs MTSR Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DYN is priced at $22.21, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DYN's ROE is -0.58%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, DYN is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MTSR's competition here
DYN vs LQDA Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, LQDA has a market cap of 7.1B. Regarding current trading prices, DYN is priced at $22.21, while LQDA trades at $79.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas LQDA's P/E ratio is 569.50. In terms of profitability, DYN's ROE is -0.58%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, DYN is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check LQDA's competition here
DYN vs PRAX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, PRAX has a market cap of 7.1B. Regarding current trading prices, DYN is priced at $22.21, while PRAX trades at $334.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas PRAX's P/E ratio is -25.04. In terms of profitability, DYN's ROE is -0.58%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, DYN is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check PRAX's competition here
DYN vs MRUS Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DYN is priced at $22.21, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DYN's ROE is -0.58%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, DYN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MRUS's competition here
DYN vs PTCT Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, PTCT has a market cap of 6.8B. Regarding current trading prices, DYN is priced at $22.21, while PTCT trades at $81.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas PTCT's P/E ratio is -35.01. In terms of profitability, DYN's ROE is -0.58%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, DYN is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check PTCT's competition here
DYN vs ACLX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DYN is priced at $22.21, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ACLX's P/E ratio is -28.27. In terms of profitability, DYN's ROE is -0.58%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, DYN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ACLX's competition here
DYN vs COGT Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, DYN is priced at $22.21, while COGT trades at $38.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas COGT's P/E ratio is -18.34. In terms of profitability, DYN's ROE is -0.58%, compared to COGT's ROE of -0.83%. Regarding short-term risk, DYN is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check COGT's competition here
DYN vs SRRK Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, DYN is priced at $22.21, while SRRK trades at $55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas SRRK's P/E ratio is -15.32. In terms of profitability, DYN's ROE is -0.58%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, DYN is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check SRRK's competition here
DYN vs RETA Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DYN is priced at $22.21, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas RETA's P/E ratio is -66.29. In terms of profitability, DYN's ROE is -0.58%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DYN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RETA's competition here
DYN vs LGND Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, DYN is priced at $22.21, while LGND trades at $316.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas LGND's P/E ratio is 37.90. In terms of profitability, DYN's ROE is -0.58%, compared to LGND's ROE of +0.16%. Regarding short-term risk, DYN is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check LGND's competition here
DYN vs CGON Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, DYN is priced at $22.21, while CGON trades at $71.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CGON's P/E ratio is -30.49. In terms of profitability, DYN's ROE is -0.58%, compared to CGON's ROE of -0.23%. Regarding short-term risk, DYN is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check CGON's competition here
DYN vs CNTA Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, DYN is priced at $22.21, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CNTA's P/E ratio is -22.63. In terms of profitability, DYN's ROE is -0.58%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, DYN is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CNTA's competition here
DYN vs BLTE Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, DYN is priced at $22.21, while BLTE trades at $153.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas BLTE's P/E ratio is -82.34. In terms of profitability, DYN's ROE is -0.58%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, DYN is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BLTE's competition here
DYN vs MIRM Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, DYN is priced at $22.21, while MIRM trades at $117.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas MIRM's P/E ratio is -8.60. In terms of profitability, DYN's ROE is -0.58%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, DYN is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MIRM's competition here
DYN vs ERAS Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ERAS has a market cap of 5.7B. Regarding current trading prices, DYN is priced at $22.21, while ERAS trades at $18.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ERAS's P/E ratio is -41.64. In terms of profitability, DYN's ROE is -0.58%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, DYN is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ERAS's competition here
DYN vs CDTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DYN is priced at $22.21, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DYN's ROE is -0.58%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, DYN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CDTX's competition here
DYN vs ABCM Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DYN is priced at $22.21, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DYN's ROE is -0.58%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DYN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ABCM's competition here
DYN vs ISEE Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DYN is priced at $22.21, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DYN's ROE is -0.58%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DYN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ISEE's competition here
DYN vs SYRE Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, SYRE has a market cap of 5.4B. Regarding current trading prices, DYN is priced at $22.21, while SYRE trades at $88.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas SYRE's P/E ratio is -42.68. In terms of profitability, DYN's ROE is -0.58%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, DYN is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check SYRE's competition here
DYN vs LEGN Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, DYN is priced at $22.21, while LEGN trades at $28.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas LEGN's P/E ratio is -42.47. In terms of profitability, DYN's ROE is -0.58%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, DYN is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check LEGN's competition here
DYN vs TVTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, DYN is priced at $22.21, while TVTX trades at $56.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas TVTX's P/E ratio is -258.23. In terms of profitability, DYN's ROE is -0.58%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, DYN is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TVTX's competition here
DYN vs CRSP Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, DYN is priced at $22.21, while CRSP trades at $54.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CRSP's P/E ratio is -10.67. In terms of profitability, DYN's ROE is -0.58%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, DYN is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CRSP's competition here
DYN vs APLS Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, DYN is priced at $22.21, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas APLS's P/E ratio is 38.35. In terms of profitability, DYN's ROE is -0.58%, compared to APLS's ROE of +0.40%. Regarding short-term risk, DYN is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check APLS's competition here
DYN vs MANE Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, MANE has a market cap of 5.1B. Regarding current trading prices, DYN is priced at $22.21, while MANE trades at $122.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas MANE's P/E ratio is -39.14. In terms of profitability, DYN's ROE is -0.58%, compared to MANE's ROE of -0.95%. Regarding short-term risk, DYN is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MANE's competition here
DYN vs DFTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, DFTX has a market cap of 5.1B. Regarding current trading prices, DYN is priced at $22.21, while DFTX trades at $47.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas DFTX's P/E ratio is N/A. In terms of profitability, DYN's ROE is -0.58%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, DYN is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check DFTX's competition here
DYN vs CELC Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CELC has a market cap of 5.1B. Regarding current trading prices, DYN is priced at $22.21, while CELC trades at $104.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CELC's P/E ratio is -26.83. In terms of profitability, DYN's ROE is -0.58%, compared to CELC's ROE of -2.45%. Regarding short-term risk, DYN is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CELC's competition here
DYN vs CAI Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CAI has a market cap of 5B. Regarding current trading prices, DYN is priced at $22.21, while CAI trades at $17.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CAI's P/E ratio is -98.02. In terms of profitability, DYN's ROE is -0.58%, compared to CAI's ROE of +0.06%. Regarding short-term risk, DYN is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CAI's competition here
DYN vs TERN Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, DYN is priced at $22.21, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas TERN's P/E ratio is -51.41. In terms of profitability, DYN's ROE is -0.58%, compared to TERN's ROE of -0.20%. Regarding short-term risk, DYN is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TERN's competition here
DYN vs XENE Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, XENE has a market cap of 4.8B. Regarding current trading prices, DYN is priced at $22.21, while XENE trades at $60.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas XENE's P/E ratio is -12.84. In terms of profitability, DYN's ROE is -0.58%, compared to XENE's ROE of -0.49%. Regarding short-term risk, DYN is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check XENE's competition here
DYN vs FOLD Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DYN is priced at $22.21, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas FOLD's P/E ratio is -161.00. In terms of profitability, DYN's ROE is -0.58%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, DYN is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check FOLD's competition here
DYN vs VKTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, VKTX has a market cap of 4.5B. Regarding current trading prices, DYN is priced at $22.21, while VKTX trades at $39.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas VKTX's P/E ratio is -9.42. In terms of profitability, DYN's ROE is -0.58%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, DYN is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check VKTX's competition here
DYN vs AKRO Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DYN is priced at $22.21, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DYN's ROE is -0.58%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, DYN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check AKRO's competition here
DYN vs ALPN Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DYN is priced at $22.21, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DYN's ROE is -0.58%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DYN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ALPN's competition here
DYN vs EWTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, DYN is priced at $22.21, while EWTX trades at $40.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas EWTX's P/E ratio is -24.65. In terms of profitability, DYN's ROE is -0.58%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, DYN is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check EWTX's competition here
DYN vs ACAD Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, DYN is priced at $22.21, while ACAD trades at $25.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ACAD's P/E ratio is 12.40. In terms of profitability, DYN's ROE is -0.58%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, DYN is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ACAD's competition here
DYN vs OPT Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DYN is priced at $22.21, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas OPT's P/E ratio is -1.52. In terms of profitability, DYN's ROE is -0.58%, compared to OPT's ROE of +1.09%. Regarding short-term risk, DYN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check OPT's competition here
DYN vs MRTX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DYN is priced at $22.21, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DYN's ROE is -0.58%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DYN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MRTX's competition here
DYN vs DNLI Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, DYN is priced at $22.21, while DNLI trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas DNLI's P/E ratio is -8.93. In terms of profitability, DYN's ROE is -0.58%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, DYN is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check DNLI's competition here
DYN vs DNTH Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, DNTH has a market cap of 4.1B. Regarding current trading prices, DYN is priced at $22.21, while DNTH trades at $97.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas DNTH's P/E ratio is -23.60. In terms of profitability, DYN's ROE is -0.58%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, DYN is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check DNTH's competition here
DYN vs NAMS Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, NAMS has a market cap of 4B. Regarding current trading prices, DYN is priced at $22.21, while NAMS trades at $33.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas NAMS's P/E ratio is -21.31. In terms of profitability, DYN's ROE is -0.58%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, DYN is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check NAMS's competition here
DYN vs CRNX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, DYN is priced at $22.21, while CRNX trades at $37.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CRNX's P/E ratio is -7.29. In terms of profitability, DYN's ROE is -0.58%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, DYN is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CRNX's competition here
DYN vs TLX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, TLX has a market cap of 3.9B. Regarding current trading prices, DYN is priced at $22.21, while TLX trades at $11.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas TLX's P/E ratio is -627.65. In terms of profitability, DYN's ROE is -0.58%, compared to TLX's ROE of -0.02%. Regarding short-term risk, DYN is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TLX's competition here
DYN vs TNGX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, DYN is priced at $22.21, while TNGX trades at $31.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas TNGX's P/E ratio is -37.66. In terms of profitability, DYN's ROE is -0.58%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, DYN is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TNGX's competition here
DYN vs NAMSW Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, NAMSW has a market cap of 3.9B. Regarding current trading prices, DYN is priced at $22.21, while NAMSW trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas NAMSW's P/E ratio is -11.81. In terms of profitability, DYN's ROE is -0.58%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, DYN is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check NAMSW's competition here
DYN vs CPRX Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, DYN is priced at $22.21, while CPRX trades at $31.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CPRX's P/E ratio is 11.31. In terms of profitability, DYN's ROE is -0.58%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DYN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CPRX's competition here
DYN vs RYZB Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DYN is priced at $22.21, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DYN's ROE is -0.58%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DYN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RYZB's competition here
DYN vs CBAY Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DYN is priced at $22.21, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DYN's ROE is -0.58%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DYN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CBAY's competition here
DYN vs ELVN Comparison July 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 3.7B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, DYN is priced at $22.21, while ELVN trades at $50.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -6.90, whereas ELVN's P/E ratio is -30.39. In terms of profitability, DYN's ROE is -0.58%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, DYN is more volatile compared to ELVN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ELVN's competition here